Published in Transplant Proc on February 01, 1987
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Transmission of hepatitis C virus by organ transplantation. N Engl J Med (1991) 5.17
Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med (1992) 2.78
Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med (1987) 2.16
Small bowel transplantation. Transplantation (1984) 1.59
Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol (2000) 1.45
Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg (1985) 1.40
Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med (1985) 1.34
Small intestine transplantation in the rat--immunology and function. Surgery (1984) 1.23
Late mortality and morbidity in recipients of long-term renal allografts. Transplantation (1982) 1.10
Metabolic aspects of small bowel transplantation in inbred rats. J Surg Res (1987) 1.08
Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation (1983) 1.04
Structural and functional evolution of jejunal allograft rejection in rats and the ameliorating effects of cyclosporine therapy. J Clin Invest (1985) 0.96
Transplantation in miniature swine. VI. Factors influencing survival of renal allografts. Transplantation (1979) 0.96
Experience with cyclosporine and steroids in clinical renal transplantation. Ann Surg (1984) 0.92
Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation (1989) 0.92
Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Transplant Proc (1991) 0.92
Transplantation in miniature swine. VII. Evidence for cellular immune mechanisms in hyperacute rejection of renal alografts. Transplantation (1979) 0.91
Monoclonal anti-IL-2 receptor antibody in primate renal transplantation. Transplant Proc (1987) 0.90
Small bowel transplantation. World J Surg (1985) 0.89
In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. Clin Cancer Res (1999) 0.89
Long-term results of cyclosporine treatment in renal transplantation. Transplant Proc (1986) 0.89
Transplantation in miniature swine. X. Evidence for non-SLA-linked immune response gene(s) controlling rejection of SLA-matched kidney allografts. Transplantation (1981) 0.86
Liver disease in recipients of long-functioning renal allografts. Kidney Int (1985) 0.83
Conversion from cyclosporine to azathioprine in renal allograft recipients. Transplantation (1984) 0.82
Cardiac allograft survival in mice treated with IL-2-PE40. Proc Natl Acad Sci U S A (1989) 0.82
Effect of repetitive doses of soluble human complement receptor type 1 on survival of discordant cardiac xenografts. Transplant Proc (1993) 0.82
The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection. Transplantation (1985) 0.82
A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial. Transplant Proc (1988) 0.82
Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody. Transplantation (1989) 0.81
Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1. Transplant Proc (1992) 0.80
Interleukin 2 receptor--a target for immunosuppressive therapy. Transplant Rev (Orlando) (1987) 0.80
Phosphorylation of the enantiomers of the carbocyclic analog of 2'-deoxyguanosine in cells infected with herpes simplex virus type 1 and in uninfected cells. Lack of enantiomeric selectivity with the viral thymidine kinase. Mol Pharmacol (1993) 0.80
Prolongation of primate renal allografts with anti-Tac monoclonal antibody. Curr Surg (1988) 0.79
Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. Transplant Proc (1988) 0.79
Renal artery stenosis in transplant patients. Ann Surg (1984) 0.78
Evidence that rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes. Transplantation (1994) 0.78
Interleukin 2 receptor expression on peripheral blood lymphocytes in association with renal allograft rejection. Transplantation (1989) 0.78
Immune function in transplanted small intestine. II: sIgA production in cholera toxin-primed rats. Transplant Proc (1990) 0.78
Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study Group. Transplant Proc (1993) 0.78
Treatment with a diphtheria toxin-related interleukin 2 fusion protein prolongs cardiac allograft survival in mice. Transplant Proc (1989) 0.77
Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine. Transplantation (1989) 0.77
Mesenteric and intraepithelial lymphocytes are insufficient to cause rejection but able to mediate lethal graft-versus-host disease in small bowel transplants. Transplant Proc (1994) 0.77
Synergism between anti-interleukin 2 receptor monoclonal antibody and cyclosporine in small-intestinal transplantation. Curr Surg (1987) 0.77
Management of general surgical complications following cardiac transplantation. Arch Surg (1989) 0.77
Low risk of liver disease after tissue transplantation from donors with HCV. Lancet (1993) 0.77
Allorecognition in T-cell receptor (beta-chain) transgenic mice. Surgery (1991) 0.77
The detection of cardiac allograft rejection by alterations in proton NMR relaxation times. Invest Radiol (1985) 0.77
Inhibitory effect of cyclosporine on specific secretory IgA production against cholera toxin in small bowel transplantation. Transplant Proc (1991) 0.76
Cyclosporine inhibits specific sIgA production against cholera toxin but not trinitrophenyl-lipopolysaccharide in small bowel transplantation. Transplant Proc (1992) 0.76
Priming the recipient abrogates the inhibitory effect of cyclosporine on specific sIgA production against cholera toxin in small bowel transplantation. Transplant Proc (1992) 0.76
Failure of cyclosporine to prevent small bowel allograft rejection in pigs. J Surg Res (1985) 0.76
Immune function in transplanted small intestine. Total secretory IgA production and response against cholera toxin. Transplantation (1990) 0.76
Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation. Am J Kidney Dis (1989) 0.76
Liver disease and HCV infection after transplantation of organs from hepatitis C antibody positive donors. Transplant Proc (1993) 0.75
Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A. Dev Biol Stand (1988) 0.75
Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts. Ann Surg (1991) 0.75
Vascular access for dialysis and cancer chemotherapy. Adv Surg (1986) 0.75
Treatment with anti-interleukin-2 receptor monoclonal antibody. Prog Clin Biol Res (1986) 0.75
In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents. Targeted Diagn Ther (1992) 0.75
Clinical experience with cyclosporine and azathioprine at Brigham and Women's Hospital. Am J Kidney Dis (1985) 0.75
Stability of renal allograft recipients after conversion from cyclosporine to azathioprine. Transplant Proc (1985) 0.75
The role of a primate model of renal transplantation in the development of new monoclonal antibodies. Am J Kidney Dis (1989) 0.75
In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic. Trans Assoc Am Physicians (1989) 0.75
Intrathymic injection of allogeneic cells induces indefinite survival of cardiac but not small bowel grafts. Transplant Proc (1994) 0.75
Successful management of catastrophic intraabdominal complications following cardiac transplantation. Transplant Proc (1989) 0.75
Insights into the mechanism of allograft acceptance in T-cell receptor (beta-chain) transgenic mice. Transplant Proc (1993) 0.75
T cell activation antigens: therapeutic implications. Immunol Invest (1988) 0.75
The use of percutaneous nephrostomy in patients with ureteric obstruction undergoing renal transplantation. Surg Gynecol Obstet (1986) 0.75
Monoclonal anti-T12 antibody as therapy for renal allograft rejection. Trans Assoc Am Physicians (1983) 0.75
Anti-T12 monoclonal antibody therapy of acute renal allograft rejection. Transplant Proc (1987) 0.75
Evidence for cellular immune mechanisms in hyperacute rejection of renal allografts in miniature swine. Transplant Proc (1979) 0.75
Anti-TAC MOAB prolongs renal allografts in cynomolgus monkeys. Transplant Proc (1989) 0.75